vs
Side-by-side financial comparison of CME Group (CME) and DaVita (DVA). Click either name above to swap in a different company.
DaVita is the larger business by last-quarter revenue ($3.6B vs $1.9B, roughly 1.9× CME Group). DaVita runs the higher net margin — 6.5% vs 0.1%, a 6.4% gap on every dollar of revenue. On growth, CME Group posted the faster year-over-year revenue change (14.5% vs 12.3%). Over the past eight quarters, CME Group's revenue compounded faster (10.8% CAGR vs 6.6%).
CME Group Inc. is an American financial services company based in Chicago, Illinois. It operates financial derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX), and the Commodity Exchange (COMEX). The company owns 27% of S&P Dow Jones Indices. It is the world's largest operator of financial derivatives exchanges. Its exchanges are platforms for trading in agricultural products, currencies, energy, i...
DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
CME vs DVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9B | $3.6B |
| Net Profit | $1.2M | $234.2M |
| Gross Margin | — | — |
| Operating Margin | 0.1% | 15.5% |
| Net Margin | 0.1% | 6.5% |
| Revenue YoY | 14.5% | 12.3% |
| Net Profit YoY | 20.7% | 43.8% |
| EPS (diluted) | — | $3.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.9B | $3.6B | ||
| Q4 25 | $1.6B | $3.6B | ||
| Q3 25 | $1.5B | $3.4B | ||
| Q2 25 | $1.7B | $3.4B | ||
| Q1 25 | $1.6B | $3.2B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.6B | $3.3B | ||
| Q2 24 | $1.5B | $3.2B |
| Q1 26 | $1.2M | $234.2M | ||
| Q4 25 | $1.2B | $234.2M | ||
| Q3 25 | $908.0M | $150.3M | ||
| Q2 25 | $1.0B | $199.3M | ||
| Q1 25 | $956.2M | $162.9M | ||
| Q4 24 | $874.6M | $259.3M | ||
| Q3 24 | $912.8M | $214.7M | ||
| Q2 24 | $883.2M | $222.7M |
| Q1 26 | 0.1% | 15.5% | ||
| Q4 25 | 61.8% | 15.5% | ||
| Q3 25 | 63.3% | 14.8% | ||
| Q2 25 | 66.7% | 15.9% | ||
| Q1 25 | 67.5% | 13.6% | ||
| Q4 24 | 62.1% | 17.2% | ||
| Q3 24 | 64.6% | 16.4% | ||
| Q2 24 | 65.3% | 15.9% |
| Q1 26 | 0.1% | 6.5% | ||
| Q4 25 | 71.7% | 6.5% | ||
| Q3 25 | 59.1% | 4.4% | ||
| Q2 25 | 60.6% | 5.9% | ||
| Q1 25 | 58.2% | 5.1% | ||
| Q4 24 | 57.3% | 7.9% | ||
| Q3 24 | 57.6% | 6.6% | ||
| Q2 24 | 57.6% | 7.0% |
| Q1 26 | — | $3.22 | ||
| Q4 25 | $3.24 | $3.22 | ||
| Q3 25 | $2.49 | $2.04 | ||
| Q2 25 | $2.81 | $2.58 | ||
| Q1 25 | $2.62 | $2.00 | ||
| Q4 24 | $2.40 | $3.08 | ||
| Q3 24 | $2.50 | $2.50 | ||
| Q2 24 | $2.42 | $2.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $700.7M |
| Total DebtLower is stronger | $3.4B | $10.2B |
| Stockholders' EquityBook value | — | $-651.1M |
| Total Assets | $202.0B | $17.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.4B | $700.7M | ||
| Q4 25 | $4.5B | $700.7M | ||
| Q3 25 | $2.6B | $736.5M | ||
| Q2 25 | $2.1B | $739.4M | ||
| Q1 25 | $1.5B | $511.9M | ||
| Q4 24 | $3.0B | $846.0M | ||
| Q3 24 | $2.4B | $1.1B | ||
| Q2 24 | $1.9B | $437.2M |
| Q1 26 | $3.4B | $10.2B | ||
| Q4 25 | — | $10.2B | ||
| Q3 25 | — | $10.2B | ||
| Q2 25 | — | $10.1B | ||
| Q1 25 | — | $9.6B | ||
| Q4 24 | — | $9.2B | ||
| Q3 24 | — | $9.3B | ||
| Q2 24 | — | $8.5B |
| Q1 26 | — | $-651.1M | ||
| Q4 25 | $28.7B | $-651.1M | ||
| Q3 25 | $28.2B | $-571.9M | ||
| Q2 25 | $27.7B | $-369.6M | ||
| Q1 25 | $27.0B | $-267.1M | ||
| Q4 24 | $26.5B | $121.1M | ||
| Q3 24 | $28.2B | $386.7M | ||
| Q2 24 | $27.6B | $632.9M |
| Q1 26 | $202.0B | $17.5B | ||
| Q4 25 | $198.4B | $17.5B | ||
| Q3 25 | $187.1B | $17.6B | ||
| Q2 25 | $179.9B | $17.5B | ||
| Q1 25 | $157.8B | $17.1B | ||
| Q4 24 | $137.4B | $17.3B | ||
| Q3 24 | $137.8B | $17.5B | ||
| Q2 24 | $123.4B | $17.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 75.76× | ||
| Q3 24 | — | 23.95× | ||
| Q2 24 | — | 13.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
